1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms E Walmsley
|
|||
b)
|
Position/status
|
Chief
Executive Officer
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
2,223.341
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Connor
|
|||
b)
|
Position/status
|
President, Global Vaccines
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
1,612.654
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Conrad
|
|||
b)
|
Position/status
|
SVP, Human Resources
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
8.690
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr J Ford
|
|||
b)
|
Position/status
|
SVP & General Counsel
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|||
b)
|
Nature
of the transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$37.7256
|
80.761
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
4f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr J Ford
|
|||
b)
|
Position/status
|
SVP & General Counsel
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
0.000030
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr N Hirons
|
|||
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
806.806
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms S Jackson
|
|||
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
198.832
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
4f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Jackson
|
|||
b)
|
Position/status
|
PCA of Ms S Jackson (SVP, Global Communications and CEO
Office)
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
84.925
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr B McNamara
|
|||
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|||
b)
|
Nature
of the transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$37.7256
|
1,077.955
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr L Miels
|
|||
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
2,780.620
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
4f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Redfern
|
|||
b)
|
Position/status
|
Chief Strategy Officer
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
3,606.925
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Simard
|
|||
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
711.276
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr P Thomson
|
|||
b)
|
Position/status
|
President, Global Affairs
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
425.020
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms K Thomson
|
|||
b)
|
Position/status
|
PCA of Mr P Thomson (President, Global Affairs)
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
147.605
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms D Waterhouse
|
|||
b)
|
Position/status
|
Chief Executive Officer of ViiV Healthcare
|
|||
c)
|
Initial
notification/
amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 October 2020
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£14.4008
|
284.256
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
Aggregated
volume Price
|
|
||||
e)
|
Date
of the transaction
|
2020-10-09
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: October
13, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|